Loading...

BridgeBio Pharma, Inc.

BBIONASDAQ
Healthcare
Biotechnology
$46.50
$3.31(7.66%)

BridgeBio Pharma, Inc. (BBIO) Stock Overview

Explore BridgeBio Pharma, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 75.8/100

Key Financials

Market Cap8.7B
P/E Ratio-13.11
EPS (TTM)$-3.56
ROE0.49%
Fundamental Analysis

AI Price Forecasts

1 Week$42.78
1 Month$35.99
3 Months$32.92
1 Year Target$37.93

BBIO Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of BridgeBio Pharma, Inc. (BBIO) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 71.04, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $37.93.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -13.11 and a market capitalization of 8.7B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

71.04RSI (14)
1.93MACD
43.62ADX
Revenue Growth
2285.27%
2285.27%
Profit Growth
$-3.51
16.70%
EPS Growth
$-3.51
27.09%
Operating Margin
-547.57%
2.37%
ROE
49.21%
16.70%
Dividend Yield
0.00%

Analyst Recommendations

Strong Buy
0
Buy
3
Hold
0
Sell
0
Strong Sell
0

Price Targets

Low$45.00
Average$52.40
High$72.00

Company Profile

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

CEO

Neil Kumar

Employees

725

Headquarters

421 Kipling Street, Palo Alto, CA

Founded

2019

Frequently Asked Questions

;